SBIR/STTR Research Award

Ultraviolet B Irradiation of Allogeneic Veins

Award identifier 965d644b39b76db1c17aff2375de43a116f9f628a0402934e0a4c39b904222f4Awarding agency Department of Health and Human Services

Award amount

$50,000

Program and phase

SBIR · Phase I

Award year

1993

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
CRYOLIFE, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

The major factor limiting more widespread utilization of allogeneic veins in arterial bypass procedures is the recipients' immune response. The intimal endothelial cells appear to be the focus of this immune response, which results in loss of the intimal lining of the vessel lumen during the first two weeks after transplantation and the longer-term risk of occlusion. This proposal will examine the hypothesis that ultraviolet B (UVB) irradiation may reduce the immunostimulatory capabilities of allogeneic canine saphenous veins, while preserving cell viability. Initial in vitro experiments will determine whether UVB irradiation of endothelial cells can induce immunological tolerance in mixed cultures of irradiated endothelial cells and non-irradiated allogeneic peripheral blood mononuclear cells. In situ experiments will then be performed, using UVB doses defined in vitro, to select a dose with maximal in vitro effect and minimal in situ losses of cell viability. An in vivo transplantation study will then be performed to determine the effects of this selected UVB irradiation dose on endothelial cell survival and allograft patency. If the results of this feasibility study are positive, human saphenous veins will be studied in the next, Phase II, grant application. Reduction of the immunological consequences of venous allografting would justify the use of allograft veins in a broad range of clinical applications.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.